Evidence map›Paper›PMID 38363519›Full record

ArticleDigestive diseases and sciences2024

Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms.

Xiaolei Wang, Die Zhu, Siyu Li, Yun Dai, Guigen Teng, Weihong Wang

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07122284 (Characterization of Gut Microbiota and Metabolic Profiles in Patients With Helicobacter Pylori Infection and Small Intestinal Bacterial Overgrowth Based on Metagenomic and Metabolomic Analyses), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07122284 completednot on this map

Characterization of Gut Microbiota and Metabolic Profiles in Patients With Helicobacter Pylori Infection and Small Intestinal Bacterial Overgrowth Based on Metagenomic and Metabolomic Analyses

TypeobservationalSponsorZhongshan Hospital (Xiamen), Fudan UniversityRan2024 to 2025Enrolled42ConditionsGut Microbiota, Metabolic Profiles, Helicobacter Pylori Infection, Small Intestinal Bacterial OvergrowthArms13C-Urea Breath Test, Hydrogen-Methane Breath Test
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaolei WangDepartment of Gastroenterology, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China.
Die ZhuDepartment of Gastroenterology, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China.
Siyu LiDepartment of Gastroenterology, Beijing Hospital, Beijing, China.
Yun DaiDepartment of Gastroenterology, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China.
Guigen TengDepartment of Gastroenterology, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China.
Weihong WangDepartment of Gastroenterology, Peking University First Hospital, No.8 Xishiku Street, Beijing, 100034, China. wangweihong2581@163.com.ORCID http://orcid.org/0000-0003-4740-7388
Peking University · CNBeijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between Helicobacter pylori (H. pylori) infection and small intestinal bacterial overgrowth (SIBO) has attracted attention recently.

aimsTo analyze the influence of H. pylori infection and eradication on SIBO, IMO, and abdominal symptoms.

methodsPatients with gastrointestinal symptoms were tested for

resultsOf the 102 subjects, 53 were H. pylori positive. The prevalence of SIBO and IMO were higher in patients with H. pylori infection than in those without infection (49.1% vs 24.5%, P = 0.019 for SIBO; 24.5% vs 8.2%, P = 0.027 for IMO). GSRS scores were similar between H. pylori-infected and uninfected patients (2 (IQR: 1;3) vs 2 (IQR: 1;2), P = 0.211). Patients with SIBO or IMO presented higher GSRS scores than patients with both SIBO and IMO negative (2 (IQR: 2;3), 2 (IQR: 2;3) vs 2 (IQR: 1;2), P = 0.011, 0.001, respectively). For the 50 patients who successfully eradicated H. pylori, the response rates for SIBO and IMO were 66.7% and 76.9%, respectively. GSRS scores also significantly decreased (2 (IQR: 1;3) to 0 (IQR: 0;1), P < 0.001) after eradication.

conclusionHelicobacter pylori infection was associated with higher prevalence of SIBO and IMO, both of which led to more pronounced abdominal symptoms. H. pylori eradication also achieved therapeutic effects on SIBO and IMO, accompanied by relief of abdominal symptoms.

Indexed as

Gastrointestinal DiseasesHelicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsBismuthBreath TestsDrug Therapy, CombinationHumansLactuloseAnti-Bacterial AgentsBismuthLactuloseAbdominal symptomsEradication treatmentHelicobacter pyloriIntestinal methanogen overgrowthSmall intestinal bacterial overgrowth

Identifiers

PMID38363519
OpenAlexW4391879894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.